<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Amylyx Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/amylyx-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Amylyx Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/amylyx-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683545ed78dffbe2df0e2c41.webp</url>
      <title>Amylyx Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
      <pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-completion-of-enrollment-in-pivotal-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-completion-of-enrollment-in-pivotal-phase-3-lucidity-clinical-trial-of-avexitide-in-post-bariatric-hypoglycemia</guid>
      <pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
      <description>Last participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants Topline data readout on</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
      <description>Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-3-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-3-2026</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2025</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-nomination-amx0318-novel-long-acting-glp-1-receptor</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-nomination-amx0318-novel-long-acting-glp-1-receptor</guid>
      <pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
      <description>AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-new-safety-and-tolerability-cohort-1-data-amx0114</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-new-safety-and-tolerability-cohort-1-data-amx0114</guid>
      <pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
      <description>- AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort -</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-11-06</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-11-06</guid>
      <pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
      <description>Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide expected in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-present-upcoming-investor-conferences-2025-11-03</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-present-upcoming-investor-conferences-2025-11-03</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-report-third-quarter-2025-financial-results-november-6-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-report-third-quarter-2025-financial-results-november-6-2025</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its third quarter 2025 financial</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-pricing-175-million-underwritten-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-pricing-175-million-underwritten-public-offering</guid>
      <pubDate>Wed, 10 Sep 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-proposed-public-offering-common-stock-2025-09-09</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-proposed-public-offering-common-stock-2025-09-09</guid>
      <pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-discontinue-orion-program-amx0035-progressive-supranuclear</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-discontinue-orion-program-amx0035-progressive-supranuclear</guid>
      <pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
      <description>- AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24 - AMX0035 continued to be generally well-tolerated</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-participate-upcoming-investor-conferences-2025-08-26</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-participate-upcoming-investor-conferences-2025-08-26</guid>
      <pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-reports-second-quarter-2025-financial-results-2025-08-07</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-reports-second-quarter-2025-financial-results-2025-08-07</guid>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <description>Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026 Cash,</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-report-second-quarter-2025-financial-results-august-7-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-report-second-quarter-2025-financial-results-august-7-2025</guid>
      <pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its second quarter 2025 financial</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-presents-new-exploratory-analyses-phase-2-and-phase-2b</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-presents-new-exploratory-analyses-phase-2-and-phase-2b</guid>
      <pubDate>Sun, 13 Jul 2025 04:00:00 GMT</pubDate>
      <description>- Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy designation, underway in</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-host-event-discuss-post-bariatric-hypoglycemia-and-avexitide</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-host-event-discuss-post-bariatric-hypoglycemia-and-avexitide</guid>
      <pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that it will host an investor</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-receives-us-fda-fast-track-designation-amx0114-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-receives-us-fda-fast-track-designation-amx0114-treatment</guid>
      <pubDate>Tue, 03 Jun 2025 04:00:00 GMT</pubDate>
      <description>- AMX0114 is an Amylyx-developed antisense oligonucleotide designed to target calpain-2, a key contributor to the axonal degeneration pathway in ALS - Phase</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-participate-upcoming-june-investor-conferences-2025-05-21</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-participate-upcoming-june-investor-conferences-2025-05-21</guid>
      <pubDate>Wed, 21 May 2025 04:00:00 GMT</pubDate>
      <description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate</description>
    </item>
    <item>
      <title>Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome</title>
      <link>https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-positive-long-term-results-phase-2-helios-clinical</link>
      <guid isPermaLink="true">https://6ix.com/company/amylyx-pharmaceuticals-inc/news/amylyx-pharmaceuticals-announces-positive-long-term-results-phase-2-helios-clinical</guid>
      <pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
      <description>Data at Week 48 demonstrated that treatment with AMX0035 led to sustained stabilization or improvement in multiple outcomes related to disease progression,</description>
    </item>
  </channel>
</rss>